K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 53.95 HKD -1.1% Market Closed
Market Cap: 16.1B HKD

Wall Street
Price Targets

Price Targets Summary
KeyMed Biosciences Inc

Wall Street analysts forecast KeyMed Biosciences Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 84.97 HKD with a low forecast of 71.46 HKD and a high forecast of 98.18 HKD.

Lowest
Price Target
71.46 HKD
32% Upside
Average
Price Target
84.97 HKD
57% Upside
Highest
Price Target
98.18 HKD
82% Upside
KeyMed Biosciences Inc Competitors:
Price Targets
ARGX
argenx SE
17% Upside
SNDX
Syndax Pharmaceuticals Inc
92% Upside
PRTA
Prothena Corporation PLC
100% Upside
688180
Shanghai Junshi Biosciences Co Ltd
28% Downside
ACAD
ACADIA Pharmaceuticals Inc
10% Upside
ORY
Oryzon Genomics SA
143% Upside
DVAX
Dynavax Technologies Corp
96% Upside
ATRA
Atara Biotherapeutics Inc
4% Downside

Revenue
Forecast

Revenue Estimate
KeyMed Biosciences Inc

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 4 years is 64%.

N/A
Past Growth
64%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Operating Income
Forecast

Operating Income Estimate
KeyMed Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat

Net Income
Forecast

Net Income Estimate
KeyMed Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KeyMed Biosciences Inc's stock price target?
Price Target
84.97 HKD

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 84.97 HKD with a low forecast of 71.46 HKD and a high forecast of 98.18 HKD.

What is KeyMed Biosciences Inc's Revenue forecast?
Projected CAGR
64%

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 4 years is 64%.

Back to Top